Women's Health

Help Shape the Future of Denosumab Treatment

As biosimilars enter the denosumab landscape, your perspective as a healthcare provider is critical in understanding what factors influence treatment decisions. This brief survey explores your views on reimbursement considerations, coding challenges, switching comfort, and drivers of biosimilar choice. As a thank you, by completing the survey, you’ll be entered into a drawing for a chance to win a $200 gift card.

Take the survey now and make your voice heard

Latest News

Investigational Psychedelic RE104 for Postpartum Depression Delivers Positive Phase 2 Results: Reunion Neuroscience Update / image credit UVA Health Anita Clayton, MD
Investigational Psychedelic RE104 for Postpartum Depression Delivers Positive Phase 2 Results: Reunion Neuroscience Update

August 18th 2025

In the RE104 group receiving the 30-mg dose, clinically meaningful reductions in the primary endpoint were seen on day 1 posttreatment and sustained through day 28 follow-up.

Cardiovascular Health
Only 1 in 5 Women Meet Heart Health Targets at Midlife, and These 4 Factors Matter Most

August 4th 2025

New Guidelines Recommend Preconception Screening in Diabetes: Daily Dose / image credit: ©New Africa/AdobeStock
New Guidelines Recommend Preconception Screening in Diabetes: Daily Dose

August 4th 2025

Maternal Depression Found to Disrupt Emotional Responsiveness, Infant Care: Daily Dose / image credit: ©New Africa/AdobeStock
Maternal Depression Found to Disrupt Emotional Responsiveness, Infant Care: Daily Dose

July 31st 2025

FDA Extends Review Period for Elinzanetant NDA for Menopausal Vasomotor Symptoms
FDA Extends Review Period for Elinzanetant NDA for Menopausal Vasomotor Symptoms

July 25th 2025

Podcasts
Latest CME Events & Activities

More News

© 2025 MJH Life Sciences

All rights reserved.